Aucuba-001
Alzheimer's Disease
Key Facts
About Aucuba Sciences
Aucuba Sciences is a private, preclinical-stage biotech focused on developing transformative therapies for neurodegenerative diseases by targeting the fundamental biology of aging. The company's core technology platform is built on research into cellular senescence and proteostasis, aiming to develop disease-modifying treatments rather than symptomatic relief. With a strong scientific foundation and experienced leadership team, Aucuba is working to advance its lead candidate toward clinical development while exploring broader applications of its aging-focused platform. The company represents a novel approach in the competitive neurodegeneration space, seeking to alter disease progression rather than merely manage symptoms.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Donanemab | Eli Lilly | Phase 3 |
| ALN-APP | Alnylam Pharmaceuticals | Phase 1 |
| Alzheimer's Disease Program | Roche | Various |
| UCB0022 | UCB | Phase 1 |
| Lecanemab (Leqembi) | Eisai | Commercial |
| ARO-MAPT | Arrowhead Pharmaceuticals | Pre-clinical |
| AMBAR® | Grifols | Clinical |
| Lu AG08854 (L1CAM mAb) | Lundbeck | Preclinical |
| DNL919 | Denali Therapeutics | Phase 1b |
| BAN2802 | BioArctic AB | Preclinical |
| Lecanemab SC | BioArctic AB | Phase 3 |
| Undisclosed Program | uniQure | Preclinical |